CN1305526C - 乙型脑炎病毒裂解疫苗及其制备方法 - Google Patents
乙型脑炎病毒裂解疫苗及其制备方法 Download PDFInfo
- Publication number
- CN1305526C CN1305526C CNB2003101103952A CN200310110395A CN1305526C CN 1305526 C CN1305526 C CN 1305526C CN B2003101103952 A CNB2003101103952 A CN B2003101103952A CN 200310110395 A CN200310110395 A CN 200310110395A CN 1305526 C CN1305526 C CN 1305526C
- Authority
- CN
- China
- Prior art keywords
- virus
- encephalitis
- vaccine
- split vaccine
- split
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 122
- 206010014599 encephalitis Diseases 0.000 title claims abstract description 95
- 238000000034 method Methods 0.000 title claims abstract description 20
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 title abstract description 6
- 241000700605 Viruses Species 0.000 claims abstract description 121
- 239000002671 adjuvant Substances 0.000 claims abstract description 10
- 239000008187 granular material Substances 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims description 26
- 238000005336 cracking Methods 0.000 claims description 25
- 230000003612 virological effect Effects 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 238000000746 purification Methods 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 238000010790 dilution Methods 0.000 claims description 9
- 239000012895 dilution Substances 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 238000000108 ultra-filtration Methods 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 5
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 201000005702 Pertussis Diseases 0.000 claims description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 3
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 230000002101 lytic effect Effects 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 229910052782 aluminium Inorganic materials 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004411 aluminium Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 241000710914 Totivirus Species 0.000 description 10
- 210000002845 virion Anatomy 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 238000011218 seed culture Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 229940031551 inactivated vaccine Drugs 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 229960003971 influenza vaccine Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000007086 side reaction Methods 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 201000002498 viral encephalitis Diseases 0.000 description 4
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 3
- 206010052369 Encephalitis lethargica Diseases 0.000 description 3
- 241000710842 Japanese encephalitis virus Species 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000013094 purity test Methods 0.000 description 3
- 238000009781 safety test method Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229940033663 thimerosal Drugs 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 101710194807 Protective antigen Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 102000035122 glycosylated proteins Human genes 0.000 description 2
- 108091005608 glycosylated proteins Proteins 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229950008679 protamine sulfate Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000005723 virus inoculator Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 241001536481 Banzi virus Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940124832 acellular pertussis vaccine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- -1 aluminum salt Chemical class 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229960003239 encephalitis vaccine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003360 nephrocyte Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000029305 taxis Effects 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
疫苗种类 | 注射前平均体重(g) | 观察期反应 | 注射后7天平均体重(g) | 结论 |
SA14株裂解疫苗(90μg) | 332 | 全部健存无异常反应 | 360 | 合格 |
P3株裂解疫苗(90μg) | 339 | 全部健存无异常反应 | 374 | 合格 |
疫苗种类 | 注射前平均体重(g) | 观察期反应 | 注射后7天平均体重(g) | 结论 |
SA14株裂解疫苗(90μg) | 19.5 | 全部健存无异常反应 | 21.8 | 合格 |
P3株裂解疫苗(90μg) | 19.5 | 全部健存无异常反应 | 22.1 | 合格 |
疫苗种类 | 中和抗体滴度 | |
中和病毒SA14 | 中和病毒P3 | |
SA14株裂解疫苗(5μg) | 1∶20 | 1∶20 |
P3株裂解疫苗(5μg) | 1∶20 | 1∶20 |
P3株全病毒疫苗 | 1∶10 | 1∶10 |
疫苗种类 | 中和指数 |
SA14株裂解疫苗(5μg) | 2.016 |
P3株裂解疫苗(5μg) | 1.890 |
P3株全病毒疫苗 | 1.618 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101103952A CN1305526C (zh) | 2003-12-29 | 2003-12-29 | 乙型脑炎病毒裂解疫苗及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101103952A CN1305526C (zh) | 2003-12-29 | 2003-12-29 | 乙型脑炎病毒裂解疫苗及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1634580A CN1634580A (zh) | 2005-07-06 |
CN1305526C true CN1305526C (zh) | 2007-03-21 |
Family
ID=34843226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101103952A Expired - Lifetime CN1305526C (zh) | 2003-12-29 | 2003-12-29 | 乙型脑炎病毒裂解疫苗及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1305526C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105688202B (zh) * | 2016-03-03 | 2019-07-19 | 四川农业大学 | 一种乙型脑炎疫苗组合物及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997004803A1 (fr) * | 1995-08-01 | 1997-02-13 | Pasteur Merieux Serums & Vaccins | Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu |
JP2000083657A (ja) * | 1998-07-13 | 2000-03-28 | Chemo Sero Therapeut Res Inst | 日本脳炎ウイルスワクチン |
WO2001076624A1 (fr) * | 2000-04-07 | 2001-10-18 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Vaccin inactive contre l'encephalite japonaise b et procede d'elaboration associe |
WO2002028426A1 (en) * | 2000-10-02 | 2002-04-11 | Glaxosmithkline Biologicals S.A. | Split enveloped virus preparation |
WO2002028422A2 (en) * | 2000-10-02 | 2002-04-11 | Glaxosmithkline Biologicals S.A. | Split enveloped virus preparation for intranasal delivery |
CN1424917A (zh) * | 1999-07-13 | 2003-06-18 | 夏威夷生物技术集团股份有限公司 | 针对黄病毒感染的重组包膜疫苗 |
-
2003
- 2003-12-29 CN CNB2003101103952A patent/CN1305526C/zh not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997004803A1 (fr) * | 1995-08-01 | 1997-02-13 | Pasteur Merieux Serums & Vaccins | Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu |
JP2000083657A (ja) * | 1998-07-13 | 2000-03-28 | Chemo Sero Therapeut Res Inst | 日本脳炎ウイルスワクチン |
CN1424917A (zh) * | 1999-07-13 | 2003-06-18 | 夏威夷生物技术集团股份有限公司 | 针对黄病毒感染的重组包膜疫苗 |
WO2001076624A1 (fr) * | 2000-04-07 | 2001-10-18 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Vaccin inactive contre l'encephalite japonaise b et procede d'elaboration associe |
WO2002028426A1 (en) * | 2000-10-02 | 2002-04-11 | Glaxosmithkline Biologicals S.A. | Split enveloped virus preparation |
WO2002028422A2 (en) * | 2000-10-02 | 2002-04-11 | Glaxosmithkline Biologicals S.A. | Split enveloped virus preparation for intranasal delivery |
Also Published As
Publication number | Publication date |
---|---|
CN1634580A (zh) | 2005-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106661102B (zh) | 作为对抗肠病毒感染之免疫原的病毒颗粒及其制造 | |
JP5095685B2 (ja) | 日本脳炎ウイルス群感染症に対する不活化ワクチンのための増強免疫原およびその製造方法 | |
CN101897963B (zh) | 一种手足口病病毒疫苗 | |
CN105963692B (zh) | 一种预防手足口病的联合疫苗 | |
CN107267466A (zh) | 一种大规模生产猪伪狂犬病灭活疫苗的方法 | |
CN103386126B (zh) | 一种含肠道病毒抗原的多价免疫原性组合物 | |
CN107746832A (zh) | 一株高滴度的柯萨奇病毒a10驯化株及其应用 | |
CN107739731A (zh) | 包含柯萨奇病毒a10驯化株的病毒组合物及其应用 | |
EP2075005B1 (en) | Ipv-dpt vaccine | |
CN1712068A (zh) | 二倍体细胞狂犬疫苗及纯化狂犬疫苗,剂型冻干及水针 | |
CN112717128B (zh) | 一种预防手足口病的联合疫苗及其制备方法和应用 | |
CN106075423B (zh) | 一种预防手足口病的联合疫苗 | |
CN105999256B (zh) | 一种预防手足口病的联合疫苗 | |
CN1305526C (zh) | 乙型脑炎病毒裂解疫苗及其制备方法 | |
CN104208666A (zh) | 一种疫苗组合物及其制备方法和应用 | |
CN1250284C (zh) | 甲型肝炎灭活疫苗 | |
CN109602899B (zh) | 一种增强病毒抗原免疫原性的皮内注射技术及其在手足口病疫苗研究中的应用 | |
CN100528227C (zh) | 乙型脑炎病毒疫苗及其制备方法 | |
EP4272755A1 (en) | Combined vaccine for preventing hand, foot and mouth disease, preparation method therefor and use thereof | |
CN1314449C (zh) | 乙型脑炎病毒疫苗和脑膜炎球菌结合疫苗组成的联合疫苗 | |
CN1299768C (zh) | 人用二倍体细胞乙型脑炎纯化疫苗的制备方法 | |
CN100413536C (zh) | 人用狂犬病裂解疫苗 | |
CN112791179B (zh) | 一种预防手足口病的联合疫苗及其制备方法和应用 | |
KR0123538B1 (ko) | 한탄바이러스, 서울바이러스, 푸우말라바이러스, 벨그라드바이러스 및 호왕바이러스 항원을 이용한 유행성출혈열 혼합백신 및 혼합진단제 | |
CN104694486B (zh) | 一种二联手足口病灭活疫苗及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: XUE PING Effective date: 20050603 Owner name: XUE PING Free format text: FORMER OWNER: ZHANG GUOMING |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050603 Address after: Beijing Fengtai District City, the Pearl River Ascot 15 unit 2302 room Applicant after: Xue Ping Address before: Beijing Fengtai District City, the Pearl River Ascot 15 unit 2302 room Applicant before: Zhang Guoming Co-applicant before: Xue Ping |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHENGDU ANTEJIN BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: XUE PING Effective date: 20131203 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 101318 SHUNYI, BEIJING TO: 610041 CHENGDU, SICHUAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131203 Address after: 610041 No. 88 Park South Road, hi tech Zone, Sichuan, Chengdu Patentee after: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. Address before: 101318 Beijing City, Shunyi District Vanke City Garden No. 902 cloud Fengge Patentee before: Xue Ping |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Split encephalitis B virus vaccine and method for preparing the same Effective date of registration: 20191021 Granted publication date: 20070321 Pledgee: Chengdu Branch of China Guangfa Bank Co.,Ltd. Pledgor: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. Registration number: Y2019990000366 |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: No.88 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610041 Patentee after: Fosun Antekin (Chengdu) Biopharmaceutical Co.,Ltd. Address before: No.88 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610041 Patentee before: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221115 Granted publication date: 20070321 Pledgee: Chengdu Branch of China Guangfa Bank Co.,Ltd. Pledgor: Fosun Antekin (Chengdu) Biopharmaceutical Co.,Ltd. Registration number: Y2019990000366 |
|
PM01 | Change of the registration of the contract for pledge of patent right | ||
PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20221115 Registration number: Y2019990000366 Pledgor after: Fosun Antekin (Chengdu) Biopharmaceutical Co.,Ltd. Pledgor before: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070321 |